US · Healthcare · Diagnostics & Research
EPS came in at 6.03 against a street estimate of 5.71 — a beat of 5.6%.
Analysts rate Thermo Fisher Scientific Inc a strong buy (24 buy, 3 hold, 1 sell out of 28) with an average price target of $690.62.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.36% |
| Vanguard Capital Management, LLC | 6.57% |
| State Street Corp | 4.55% |
| FMR Inc | 3.81% |
| Morgan Stanley - Brokerage Accounts | 2.91% |
| JPMorgan Chase & Co | 2.30% |
| Geode Capital Management, LLC | 2.27% |
| Franklin Templeton Inc | 1.97% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 THERMO FISHER SCIENTIFIC INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q2 2026: $11,994 million (Q2 2025: $10,855 million) — up 10.5 | 2026-07-31 |
| Results announced · Q3 2026 THERMO FISHER SCIENTIFIC Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $11.99 billion, up 10% vs. Q2 2025 ($10.85 billion) • Organic | 2026-07-23 |
| Shareholder vote results · Q2 2026 THERMO FISHER SCIENTIFIC INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 20, 2026 • 315.7 million total votes cast ac | 2026-05-26 |
| Quarterly report · Q1 2026 THERMO FISHER SCIENTIFIC INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $11,005 million (vs. $10,364 million Q1 2025), up 6. | 2026-05-01 |
| Results announced · Q2 2026 THERMO FISHER SCIENTIFIC Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $11.01 billion, up 6% from $10.36 billion in Q1 2025 • GAAP Di | 2026-04-23 |
| Proxy statement · Q2 2026 THERMO FISHER SCIENTIFIC PROXY STATEMENT SUMMARY CEO TOTAL COMPENSATION Marc N. Casper (CEO) received $65,706,258 in 2025 total compensation—a signi | 2026-04-07 |
| Company announcement · Q1 2026 THERMO FISHER SCIENTIFIC INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition completed: Thermo Fisher Scientific completed its acquisition of Cla | 2026-03-24 |
| Annual report FY2025 THERMO FISHER SCIENTIFIC INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Thermo Fisher Scientific Inc. (NYSE: TMO), Delaware co | 2026-02-26 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.47 / share ex-date Sep 15, 2026 · pay Oct 15, 2026 | 2026-09-15 |
| Dividend | $0.47 / share ex-date Jun 15, 2026 · pay Jul 15, 2026 | 2026-06-15 |
| Dividend | $0.47 / share ex-date Mar 13, 2026 · pay Apr 15, 2026 | 2026-03-13 |
| Dividend | $0.43 / share ex-date Dec 15, 2025 · pay Jan 15, 2026 | 2025-12-15 |
| Dividend | $0.43 / share ex-date Sep 15, 2025 · pay Oct 15, 2025 | 2025-09-15 |
| Announcement | Date |
|---|---|
| Completion of acquisition of Clario Holdings, Inc. Thermo Fisher Scientific completed its acquisition of Clario Holdings, Inc. on March 24, 2026. Clario is a clinical research organization (CRO) that provides drug development and clinical tr | 2026-03-24 |
| Definitive agreement to acquire Clario Holdings for approximately $8.875 billion Thermo Fisher Scientific announced on October 29, 2025, that it will acquire Clario Holdings, Inc. for approximately $8.875 billion in upfront cash, plus $125 million in deferred payments an | 2025-10-29 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Thermo Fisher Scientific Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.